To compare the effects of rizatriptan and patients’ usual migraine medication(s) on health-related quality of life.
Design and Setting
The study was a non-blinded, parallel-group, extension trial in which patients who had completed a randomised, placebo-controlled trial of the treatment of migraine with rizatriptan at 23 study sites in the United States were randomly assigned in a 4: 1 ratio either to rizatriptan or to standard care.
265 migraineurs, 18 to 65 years of age.
Patients received either rizatriptan 10mg or their usual migraine medication(s).
Main Outcome Measures and Results
The main outcome measures were: (a) migraine-specific quality of life during the 24-hour period of an attack, as determined by the 24-Hour Migraine-Specific Quality-of-Life Questionnaire (24-HrMQoLQ), for attacks in the first month; (b) general health-related quality of life as determined by the eight domain scores and the Mental and Physical Component Scales of the Short Form Health Survey (SF-36) after 2, 6 and 12 months. The 24-HrMQoLQ domains were scored from 3 to 21, and the SF-36 from 0 to 100, higher scores indicating better performance for both instruments. Patients receiving rizatriptan had significantly better scores in all five domains of the 24-HrMQoLQ compared with patients receiving standard care. Mean scores (standard error) for the rizatriptan and usual care groups were, respectively: Work Functioning, 13.9 (0.4), 12.5 (0.8), p = 0.05; Social Functioning, 13.6 (0.4), 11.8 (0.8), p = 0.015; Energy/Vitality, 13.7 (0.5), 11.6 (0.8), p < 0.01; Feelings/Concerns 13.3 (0.4), 10.6 (0.8), p < 0.001; and Migraine Symptoms 14.1 (0.4), 12.1 (0.7), p < 0.01. There was a trend for patients receiving rizatriptan to have higher scores on the Mental Component Scale of the SF-36: mean score (SE) 50.3 (0.6) for rizatriptan, 48.0 (1.1) for usual care, p = 0.068. There was no difference between the treatment groups in the Physical Component Scale: mean score (SE) 48.4 (0.6) for rizatriptan, 49.7 (1.1) for usual care, p = 0.202.
Quality of life in the 24-hour period following a migraine attack was better in patients treated with rizatriptan 10mg than in patients treated with their usual migraine medication.